Lipella Pharmaceuticals Inc. 8-K Report: Insights & Key Updates as of December 31, 2024

Based on the provided section of the financial report, here are the key insights:

1. Company Information:

• Name: Lipella Pharmaceuticals Inc.
• CIK Number: 0001347242
• State of Incorporation: Delaware (DE)
• IRS Employer Identification Number: 20-2388040
• Address: 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208
• Contact Number: (412) 894-1853

2. Filing Details:

• Filing Type: 8-K (a report of unscheduled material events or corporate changes)
• Filing Date: December 31, 2024

3. Stock Information:

• Common Stock Par Value: $0.0001 per share
• Ticker Symbol: LIPO
• Exchange: NASDAQ

4. Financial Reporting Context:

• Reporting Period: The report covers the date December 31, 2024, indicating it is likely a year-end report or a significant event as of that date.

5. Units of Measure:

• The financial figures are reported in US Dollars (USD) and Shares.

Insights:

• The report details a significant filing for Lipella Pharmaceuticals, possibly indicating important corporate activities or financial updates for investors and stakeholders.
• The company is publicly traded on NASDAQ, which may affect its regulatory obligations and disclosures.
• The date of the report is important as it may correlate with year-end financial results or other significant corporate events.

This information is crucial for stakeholders looking to understand the company's financial position and potential market actions.